(Q54088446)

24 May 2018

title

Hypertension and insulin resistance: role of peroxisome proliferator-activated receptor gamma. (English)

1 reference

24 May 2018

1 reference

1 reference

Itoh H

1

1 reference

24 May 2018

Doi K

2

1 reference

24 May 2018

Tanaka T

3

1 reference

24 May 2018

Fukunaga Y

4

1 reference

24 May 2018

Hosoda K

5

1 reference

24 May 2018

Inoue G

6

1 reference

24 May 2018

Nishimura H

7

1 reference

24 May 2018

Yoshimasa Y

8

1 reference

24 May 2018

Yamori Y

9

1 reference

24 May 2018

Nakao K

10

1 reference

24 May 2018

publication date

1 July 1999

1 reference

24 May 2018

Clinical and Experimental Pharmacology and Physiology

published in

1 reference

24 May 2018

volume

26

1 reference

24 May 2018

issue

7

1 reference

24 May 2018

page(s)

558-560

1 reference

24 May 2018

Banting lecture 1988. Role of insulin resistance in human disease

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03082.X

Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03082.X

Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03082.X

Ciglitazone, a New Hypoglycemic Agent: I. Studies in ob/ob and db/db Mice, Diabetic Chinese Hamsters, and Normal and Streptozotocin-Diabetic Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03082.X

Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03082.X

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03082.X

Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03082.X

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03082.X

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03082.X

mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03082.X

Hyperinsulinemia. A link between hypertension obesity and glucose intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03082.X

Vascular biology and medicine in the 1990s: scope, concepts, potentials, and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03082.X

Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system"

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03082.X

Vascular natriuretic peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03082.X

Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1681.1999.03082.X

10.1046/J.1440-1681.1999.03082.X

21 January 2018

Identifiers

DOI

1 reference

24 May 2018

PubMed ID

10405788

1 reference

24 May 2018